MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
VENLO, the Netherlands --(BUSINESS WIRE)-- 19.04.2018 --
QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) announced today that has posted its 2017 Annual Report on its website at http://financialreport.qiagen.com.
QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2017, was filed with the U.S. Securities and Exchange Commission (SEC) on March 6, 2018, a copy of which can be found on the website of the SEC at www.sec.gov or in the "Financial Information" section of the "Investors" section of our website at http://www.qiagen.com/About-Us/Investors/.
QIAGEN will provide printed copies of the 2017 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 2017 Annual Report please contact: IR@qiagen.com.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of December 31, 2017, QIAGEN employed approximately 4,700 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
Vice President, Head of Corporate Communications and Investor Relations
Phone +1-240-686-2222 | Fax +1-240-686-22238
Phone +49-2103-29-11711 | Fax +49-2103-29-21711
Dr. Sarah Fakih
Director Investor Relations
Phone +49-2103-29-11457 | Fax +49-2103-29-21457